Journal of Surgery Concepts & Practice >

2021 , Vol. 26 >Issue 01: 34 - 37

DOI: https://doi.org/10.16139/j.1007-9610.2021.01.007

Experts forum

Study on intraperitoneal chemotherapy in treatment of peritoneal metastatic colorectal cancer

Expand

Received date: 2021-01-19

  Online published: 2022-07-28

Fold

Cite this article

CHENG Guozhu, CAI Guoxiang . Study on intraperitoneal chemotherapy in treatment of peritoneal metastatic colorectal cancer[J]. Journal of Surgery Concepts & Practice, 2021 , 26(01) : 34 -37 . DOI: 10.16139/j.1007-9610.2021.01.007

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30.
[2] Franko J, Shi Q, Goldman CD, et al. Treatment of co-lorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase Ⅲ trials N9741 and N9841[J]. J Clin Oncol, 2012, 30(3):263-267.
[3] Mo S, Cai G. Multidisciplinary treatment for colorectal peritoneal metastases: review of the literature[J]. Gastroenterol Res Pract, 2016, 2016:1516259.
[4] Aoyagi T, Terracina KP, Raza A, et al. Current treatment options for colon cancer peritoneal carcinomatosis[J]. World J Gastroenterol, 2014, 20(35):12493-12500.
[5] Yurttas C, Hoffmann G, Tolios A, et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer[J]. J Clin Med, 2018, 7(12):567.
[6] Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer[J]. Ann Surg Oncol, 2008, 15(9):2426-2432.
[7] Cashin PH, Mahteme H, Spang N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial[J]. Eur J Cancer, 2016, 53:155-162.
[8] Quenet J, Elias D, Roca L, et al. A UNICANCER phase Ⅲ trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7[J]. J Clin Oncol, 2018, 36(18 suppl):LBA3503.
[9] Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO,MOS, SSO and TOS[J]. Ann Oncol, 2018, 29(1):44-70.
[10] 赵志勋, 裴炜, 熊斌, 等. 结直肠癌腹膜转移诊治中国专家意见(2017)[J]. 中华结直肠疾病电子杂志, 2017, 6(5):360-366.
[11] Woeste MR, Philips P, Egger ME, et al. Optimal perfusion chemotherapy: a prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer[J]. J Surg Oncol, 2020, 121(8):1298-1305.
[12] Steffen T, Eden J, Bijelic L, et al. Patient selection for hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer: consensus on decision making among international experts[J]. Clin Colorectal Cancer, 2020, 19(4):277-284.
[13] Qiu C, Li Y, Liang X, et al. A study of peritoneal metastatic xenograft model of colorectal cancer in the treatment of hyperthermic intraperitoneal chemotherapy with raltitrexed[J]. Biomed Pharmacother, 2017, 92:149-156.
[14] Roy P, Canet-Jourdan C, Annereau M, et al. Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: preclinical models to improve HIPEC[J]. Int J Pharm, 2017, 531(1):143-152.
[15] Ubink I, Bolhaqueiro ACF, Elias SG, et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy[J]. Br J Surg, 2019, 106(10):1404-1414.
[16] Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase Ⅱ/Ⅲ trial[J]. Int J Cancer, 2010, 127(9):2209-2221.
[17] Jordan K, Luetkens T, Gog C, et al. Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: a multicentre double-blind, placebo-controlled phase Ⅱ study-AIO SUP-0108[J]. Eur J Cancer, 2016, 63:127-134.
[18] Gong Q, Song C, Wang X, et al. Hyperthermic intraperitoneal chemotherapy with recombinant mutant human TNF-α and raltitrexed in mice with colorectal-peritoneal carcinomatosis[J]. Exp Biol Med (Maywood), 2020, 245(6):542-551.
[19] Frøysnes IS, Andersson Y, Larsen SG, et al. Novel treatment with intraperitoneal MOC31PE immunotoxin in co-lorectal peritoneal metastasis: results from the immunoPeCa phase 1 trial[J]. Ann Surg Oncol, 2017, 24(7):1916-1922.
[20] Frøysnes IS, Andersson Y, Larsen SG, et al. ImmunoPeCa trial: long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis[J]. Eur J Surg Oncol, 2021, 47(1):134-138.
[21] Solass W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressu-rized aerosol as an alternative to liquid solution: first evidence for efficacy[J]. Ann Surg Oncol, 2014, 21(2):553-559.
[22] Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications[J]. Lancet Oncol, 2019, 20(7):e368-e377.
[23] Demtröder C, Solass W, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis[J]. Colorectal Dis, 2016, 18(4):364-371.
[24] Siebert M, Alyami M, Mercier F, et al. Pressurized intraperitoneal aerosol chemotherapy(PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. a single center comparative study[J]. Eur J Surg Oncol, 2021, 47(1):139-142.
[25] Teixeira Farinha H, Grass F, Labgaa I, et al. Inflammatory response and toxicity after pressurized intraperitoneal aerosol chemotherapy[J]. J Cancer, 2018, 9(1):13-20.
[26] Larbre V, Alyami M, Mercier F, et al. No renal toxicity after repeated treatment with pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with unresectable peritoneal metastasis[J]. Anticancer Res, 2018, 38(12):6869-6875.
[27] Girshally R, Demtroder C, Albayrak N, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. World J Surg Oncol, 2016, 14(1):253.
Options
Outlines

/

〈 〉